Clinical trialPhase 1Completed
A Phase I Study of Recombinant hGM-CSF Herpes Simplex Virus to Treat Cancer
A Phase I Study of Recombinant hGM-CSF Herpes Simplex Virus
- Outcome
- Finished, no results posted
- Phase
- Phase 1
- Status
- Completed
- Study type
- Interventional
- Start
- May 2012
- Enrollment
- 18 participants
- Sites
- 2
- Primary outcomes
- Exploring the MTD of OrienX010 according to DLT,which defined as the serious degree of adverse events relates to the medicine not less than grade 3 of CTCAE v4.03
- Sponsor type
- Industry
- Results posted
- No
- Last update
- 1 September 2016
These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
The main purpose of this study is to study the safety of OrienX010 in the treatment of kinds of solid tumors such as melanoma,liver cancer,pancreatic cancer and lung cancer.